Telmisartan Metformin in Downregulating Myostatin Gene Expression and Enhancing Insulin Sensitivity in the Skeletal Muscles of Type 2 Diabetic Rat Model

Overview

Journal Front Pharmacol

Date 2023 Aug 14

PMID 37576807

Authors

Ahmed Abd-Eltawab Tammam

Waleed Y Rizg

Amy Fakhry Boushra

Maha Alhelf

Mohammed Alissa

Ghada F Soliman

Ghada Nady Ouais

Khaled M Hosny

Hala M Alkhalidi

Ahmed Magdy Elebiary

Affiliations

Soon will be listed here.

Abstract

Telmisartan is an angiotensin receptor blocker (ARB) that specifically blocks angiotensin II type-1 receptors (AT1R). Telmisartan has been proven to have antidiabetic effects via a variety of mechanisms, and it can be utilized in some diabetic patients due to its dual benefit for hypertensive patients with type 2 DM (T2DM) and when the other oral antidiabetic medications are intolerable or contraindicated. However, its precise underlying hypoglycemic mechanism is still obscure. We sought to establish a link between telmisartan administration and myostatin expression in skeletal muscles of T2DM rat model as a potential hypoglycemic mechanism of telmisartan. 32 male albino rats were included in the study; 8 rats served as controls (group I). T2DM was inducted in the other 24 rats, which were then randomly subdivided into 3 groups (8 in each): (group II) the Diabetic group and (groups III and IV) which were treated with either telmisartan (8 mg/kg/day) or metformin (250 mg/kg/day) respectively via oral gavage for a 4-week period. Telmisartan administration resulted in a significant improvement in OGTT, HOMA-IR, glucose uptake, and muscle mass/body ratios in Telmisartan group as compared to Diabetic group ( < 0.05). Additionally, telmisartan induced a significant boost in adiponectin and IL-10 serum levels with a substantial drop in TNF-α and IL-6 levels in Telmisartan group compared to diabetic rats ( < 0.05). Moreover, telmisartan significantly boosted SOD and GSH, and decreased MDA levels in the skeletal muscles of telmisartan group. Furthermore, a significant downregulation of myostatin and upregulation of insulin receptor, IRS-1, and IRS-3 genes in the skeletal muscles of Telmisartan group were also detected. Histologically, telmisartan attenuated the morphological damage in the skeletal muscle fibers compared to diabetic rats, as evidenced by a considerable decrease in the collagen deposition area percentage and a reduction in NF-kB expression in the muscle tissues of group III. Telmisartan administration dramatically reduced myostatin and NF-kB expressions in skeletal muscles, which improved insulin resistance and glucose uptake in these muscles, highlighting a novel antidiabetic mechanism of telmisartan in treating T2DM.

References

Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S . Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011; 54(6):1491-501. DOI: 10.1007/s00125-011-2079-7. View

Liu X, Bauman W, Cardozo C . Myostatin inhibits glucose uptake via suppression of insulin-dependent and -independent signaling pathways in myoblasts. Physiol Rep. 2018; 6(17):e13837. PMC: 6121119. DOI: 10.14814/phy2.13837. View

Andersson C, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U . Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev. 2008; 24(8):595-603. DOI: 10.1002/dmrr.889. View

Tyagi S, Gupta P, Saini A, Kaushal C, Sharma S . The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2012; 2(4):236-40. PMC: 3255347. DOI: 10.4103/2231-4040.90879. View

Watanabe M, Inukai K, Sumita T, Ikebukuro K, Ito D, Kurihara S . Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med. 2010; 49(17):1843-7. DOI: 10.2169/internalmedicine.49.3189. View

Oguntibeju O . Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019; 11(3):45-63. PMC: 6628012. View

Mourkioti F, Rosenthal N . NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med (Berl). 2008; 86(7):747-59. PMC: 2480606. DOI: 10.1007/s00109-008-0308-4. View

Cheng K, Li Y, Chang W, Kuo F, Chen Z, Cheng J . Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report. Diabetes Metab Syndr Obes. 2018; 11:901-911. PMC: 6290862. DOI: 10.2147/DMSO.S187092. View

Camporez J, Petersen M, Abudukadier A, Moreira G, Jurczak M, Friedman G . Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci U S A. 2016; 113(8):2212-7. PMC: 4776508. DOI: 10.1073/pnas.1525795113. View

10.

Gandhi G, Jothi G, Antony P, Balakrishna K, Paulraj M, Ignacimuthu S . Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling.... Eur J Pharmacol. 2014; 745:201-16. DOI: 10.1016/j.ejphar.2014.10.044. View

11.

Rotter V, Nagaev I, Smith U . Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278(46):45777-84. DOI: 10.1074/jbc.M301977200. View

12.

Pan S, Zhang L, Liu Z, Xing H . Myostatin suppresses adipogenic differentiation and lipid accumulation by activating crosstalk between ERK1/2 and PKA signaling pathways in porcine subcutaneous preadipocytes. J Anim Sci. 2021; 99(12). PMC: 8711698. DOI: 10.1093/jas/skab287. View

13.

Horii N, Sato K, Mesaki N, Iemitsu M . Increased Muscular 5α-Dihydrotestosterone in Response to Resistance Training Relates to Skeletal Muscle Mass and Glucose Metabolism in Type 2 Diabetic Rats. PLoS One. 2016; 11(11):e0165689. PMC: 5104401. DOI: 10.1371/journal.pone.0165689. View

14.

Hasegawa G, Fukui M, Hosoda H, Asano M, Harusato I, Tanaka M . Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats. Eur J Pharmacol. 2009; 605(1-3):164-9. DOI: 10.1016/j.ejphar.2009.01.001. View

15.

Yang X, Sun L, Xu P, Gong L, Qiang G, Zhang L . Effects of salvianolic scid A on plantar microcirculation and peripheral nerve function in diabetic rats. Eur J Pharmacol. 2011; 665(1-3):40-6. DOI: 10.1016/j.ejphar.2011.03.054. View

16.

Akinci B, Yener S, Bengi G, Yesil S . Alterations of coagulation in metformin intoxication. Hormones (Athens). 2009; 7(4):325-9. DOI: 10.14310/horm.2002.1214. View

17.

Bonetto A, Andersson D, Waning D . Assessment of muscle mass and strength in mice. Bonekey Rep. 2015; 4:732. PMC: 4549925. DOI: 10.1038/bonekey.2015.101. View

18.

Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J . Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011; 91(6):932-44. DOI: 10.1038/labinvest.2011.45. View

19.

Mohamed M, Hafez H, Zenhom N, Mohammed H . Cilostazol alleviates streptozotocin-induced testicular injury in rats via PI3K/Akt pathway. Life Sci. 2018; 198:136-142. DOI: 10.1016/j.lfs.2018.02.038. View

20.

Glass D, Roubenoff R . Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci. 2010; 1211:25-36. DOI: 10.1111/j.1749-6632.2010.05809.x. View